Form 4: Intellia Therapeutics Director Sells Shares Under 10b5-1 Trading Plan

Muna Bhanji, a director at Intellia Therapeutics, sold 265 shares of common stock at $9.97 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Muna Bhanji, a director at Intellia Therapeutics, sold 265 shares of the company's common stock.
• The sale occurred on January 29, 2025, at a price of $9.97 per share.
• The transaction was executed automatically under a 10b5-1 trading plan adopted on September 27, 2024.
• Following the transaction, Bhanji directly owns 19,468 shares of Intellia Therapeutics stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to a pre-planned stock sale by a director. It does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives and directors to use 10b5-1 trading plans to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among corporate insiders at publicly traded companies, including those in the biotechnology sector like Intellia Therapeutics.
• Similar filings are regularly made by directors and officers at companies like CRISPR Therapeutics and Editas Medicine, which are also involved in gene editing technologies.
• The volume of shares sold is relatively small compared to the total outstanding shares of Intellia, suggesting this is a routine transaction rather than a significant change in insider sentiment.

Stakeholder Impact

• The sale of shares by a director may have a minor impact on shareholder sentiment, but the pre-planned nature of the transaction mitigates any significant concerns.

Key Dates

Keywords

Intellia Therapeutics, NTLA, insider trading, Form 4, 10b5-1 trading plan, stock sale, Muna Bhanji, director